Pinnacle Activity Ticker
Vol. 190 - Outperforming The Market: Stellar Biotechnologies & Medallion Resources
We are just days away from announcing our new Featured Company operating within the oil and gas sector. Our team anticipates completing the research report on the company by this Wednesday. Upon completion, it will be sent to all of our members via email.
In case you missed our report last weekend with detailed information on the sector our new Featured Company operates in, you can read it by clicking the link below.
Vol. 189 - Oil Shale - The Next Wave of Domestic Production in the United States
This past week provided a breakthrough for two of our current Featured Companies:
Stellar Biotechnologies and Medallion Resources.
Both companies' share prices skyrocketed late in the week, providing our members and team with a golden opportunity.
As many of you know, we introduced Stellar Biotechnologies (KLH:TSXV) just over 5 weeks ago as our new Featured Biotech Company. The concept behind this company was something we had never seen before and after taking a trip down to Southern California to conduct further due diligence, our team knew we had to introduce Stellar to our members. Certain investment opportunities jump out at you and Stellar was certainly one of them.
When we introduced Stellar Biotechnologies to our members on September 8, 2010, its share value was $0.32. This past Thursday, just over 5 weeks after our introduction, the company's shares hit $0.64 - good for a 100% increase. That type of a return in such a short period of time is tough to beat, however, we are particularly pleased with the development Stellar has shown since we introduced it. It's one thing for a share price to double, but another to see the company developing and making a deal with a world leading biopharmaceutical giant.
Since our introduction of Stellar Biotechnologies, the company:
- Achieved a key milestone in cooperation with Bayer Innovation
- Filed another key patent
- Received payment of US$ 288,000 for a filled order of Stellar KLH/SUBUNIT from French biotechnology and active immunotherapy technology-platform company, Neovacs SA (EN Paris: ALNEV.FP)
- Has begun discussions with Celldex, which had its KLH-based brain cancer vaccine being tested in patients at Duke University featured on CBS Evening News with Katie Couric - click here to watch CBS video
- Closed a CDN $1.05M private placement with a strategic investor and retired 1.66 million shares to the treasury
All this in just over 5 weeks...
What's next for Stellar and what are its investors looking forward to?
- The status of grants that have been applied for by Stellar's California subsidiary
- Launch date for sales of immunotox products aimed at the pre-clinical market, related to Stellar's ongoing research designed to advance Stellar's immune response diagnostic platform
- Research and regulatory developments related to Stellar's new IMG KLH product platform
- Advancements related to Stellar's relationships with Bayer Innovation and several new customers
- In and out-licensing and long-term supply agreements, as well as new KLH orders.
In case you missed our exclusive research report on Stellar Biotechnologies, please feel free to read it by clicking the link below.
Vol. 184 - Our New Featured Company Has Arrived: Stellar Biotechnologies
Next on the docket this week is Medallion Resources (MDL:TSXV), a company we introduced back in March of this year at $0.20 per share. Medallion operates in the white hot rare earth sector and is partnered with one of the biggest players in the industry, Rare Element Resources. On Friday, Medallion's shares closed at $0.58 - good for a 190% return from the price it was trading at when we introduced it to our members.
We've documented this company's progress well over the last 7 months as it has followed through with consistent development for its shareholders. When we introduced it to our members, the rare earth sector hadn't made mainstream headlines yet and Medallion was relatively unknown with a very small following - a situation we particularly like to get involved with. Getting involved with the right companies before the masses is a key strategy for us when investing in the small-cap market.
In our introductory research report on Medallion we stated "As we previously mentioned, we are interested in companies which have yet to conclude significant drill programs but are sitting on well respected rare earth assets, leaving time and room for the street to speculate on their true value. As we've seen in prior situations with specific rare earth companies, positive property development can lead to massive share price increases. We have been following the management of one team in particular that we'd like to bring to your attention."
When Rare Element Resources' ex-CEO, Dr. Bill Bird, resurfaced and restructured Medallion Resources (MDL:TSXV) to search for an economic rare earth metals deposit, we put our name behind his new venture. And it has paid off.
We documented in our first research report on Medallion that Bill Bird was the CEO of Rare Element Resources from July 2005 to October 2007. It must be noted that, during his tenure with the company, Rare Element's share price increased from a low of $0.17 to $1.60 per share and saw its market capitalization more than quadruple. Dr. Bill Bird was pivotal in setting the stage for Rare Element Resources' continued growth (currently trades at $7.65). Also, during his tenure with Rare Element Resources, Dr. Bird struck a deal with Newmont Mining, signing a definitive joint-venture agreement to explore Rare Element Resources' Bear Lodge property for gold.
Strong, proven management goes a long way, especially in the small-cap market, where a company's most important asset is the expertise of its management team.
In case you missed our exclusive research report on Medallion released back in March, please click the link below.
Vol. 158 - THE RARITY OF RARE EARTH COMPANIES : Medallion Resources
Congratulations to all our members who got involved with Stellar Biotechnologies and Medallion Resources. It has been another great year for Pinnacle and we are pleased you've been with us for it.
This week we will be introducing our new Featured Company. The expertise and track record of its management is very hard to find in the small-cap market. On top of that, it's a company that is still unknown to the investing public despite the strength of its assets. We very much look forward to introducing our new Featured Company to you this coming Wednesday. Until then, have a great start to the week.
All the best with your investments,
Disclaimer: Please read carefully before proceeding. PinnacleDigest.com is an online financial newsletter owned by Maximus Strategic Consulting Inc. We are focused on researching small-cap and large-cap public companies. Nothing in this article should be construed as a solicitation to buy or sell any securities (including Stellar Biotechnologies, Medallion Resources and our upcoming featured company) mentioned anywhere in this newsletter.The author of this article bears no liability for losses and/or damages arising from the use of this article.
Forward-looking statements: This report contains certain "forward-looking" statements and information relating to Stellar Biotechnologies that are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors and strategic partners, the interest rate environment, governmental regulation and supervision, seasonality, technological change, changes in industry practices, and one-time events. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described in this report and in the company's news releases.
All statements in this report, other than statements of historical facts, that address future production, reserve potential, exploration drilling, exploitation activities and events or developments that Medallion Resources expects are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and those actual results or developments may differ materially from those projected in the forward-looking statements. For more information on the Company, Investors should review the Company's registered filings what are available at www.sedar.com .
Be advised, Maximus Strategic Consulting Inc., PinnacleDigest.com and its employees are not a registered broker-dealer or financial advisor. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer.
PinnacleDigest.com's past performance is not indicative of future results and should not be used as a reason to purchase any security mentioned in our newsletter or on our website. Most companies featured in our newsletter, and on our website, are paying clients of ours and in many cases we own shares in the companies we feature. For those reasons, please be aware that we are extremely bias in regards to the companies we write about and feature in our newsletter and on our website. Any decision to purchase or sell as a result of the opinions expressed in this report OR ON PinnacleDigest.com will be the full responsibility of the person authorizing such transaction. Information in this report has been obtained from sources considered to be reliable, but we do not guarantee that it is accurate or complete. Our views and opinions regarding the companies we feature on PinnacleDigest.com and in this newsletter are our own views and are based on information that we have received, which we assumed to be reliable. We do not guarantee that any of the companies mentioned will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect.
Maximus Strategic Consulting inc., owner of PinnacleDigest.com, its officers, directors, employees, and consultants shall not be liable for any damages, losses, or costs of any kind or type arising out of or in any way connected with the use of its products or services, including this article. Maximus Strategic Consulting Inc, owner of PinnacleDigest.com, its employees, consultants and affiliates are not responsible for any claims made by any of the mentioned companies. You should independently investigate and fully understand all risks before investing. We want to remind you again that PinnacleDigest.com is often paid editorial fees for its writing and the dissemination of material and the companies featured do not have to meet any specific financial criteria. The clients represented by PinnacleDigest.com are typically development-stage companies that pose a much higher risk to investors. When investing in speculative stocks of this nature, it is possible to lose your entire investment over time. Set forth below is our disclosure of compensation received from our clients mentioned in this newsletter and an explanation as to which companies we own shares in.
Maximus Strategic Consulting Inc., owner of PinnacleDigest.com, has been compensated to perform research on Medallion Resources Ltd. and display advertisements about the company on the www.pinnacledigest.com website. Maximus Strategic Consulting Inc., owner of PinnacleDigest.com, has been paid $40,000 Canadian dollars plus gst for advertisement coverage on Medallion Resources Ltd. The company (Medallion Resources) has paid for this service. The service includes but is not limited to the creation and distribution of reports authored by PinnacleDigest.com. We (Maximus Strategic Consulting Inc.) participated in Medallion Resources private placement at $0.175. Each Unit Maximus Strategic Consulting Inc. purchased in Medallion Resources' private placement at $0.175 consisted of one of the Company's common shares and one transferable common-share purchase warrant (a "Warrant"). Each Warrant is exercisable to acquire one common share at an exercise price of $0.30 until January 20, 2012 (we have excercised and sold every one of our warrants). All the shares we purchased in Medallion Resources' private placement are now free trading and we have sold every share we purchased in the company's private placement. Since our coverage began on Medallion Resources on March 07, 2010 we have bought and sold shares of the company on the open market. We currently do not own shares of Medallion Resources. However, we may decide to purchase more shares without notice to our subscribers. And we may decide to sell any shares we may purchase without notice to our subscribers.
Maximus Strategic Consulting Inc., owner of PinnacleDigest.com, has been paid $40,000 Canadian dollars plus gst for advertisement coverage on Stellar Biotechnologies, Inc. The company (Stellar Biotechnologies, Inc.) has paid for this service. The service includes but is not limited to the creation and distribution of reports authored by PinnacleDigest.com about Stellar Biotechnologies, Inc. Maximus Strategic Consulting Inc., owner of PinnacleDigest.com, has subscribed to Stellar Biotechnologies' recently announced Private Placement. Maximus Strategic Consulting Inc. has purchased 70,000 units (the "Units") at a price of $0.28 per unit in Stellar Biotechnologies. Each Unit is comprised of one common share and one non-transferrable share purchase warrant (a "Warrant") at $0.40. The units we (Maximus Strategic Consulting Inc.) purchased in Stellar Biotechnologies' private placement are now free trading. We (Maximus Strategic Consulting Inc. and its employees) have also bought shares in Stellar Biotechnologies on the open market. We (Maximus Strategic Consulting Inc. and its employees) have sold shares in Stellar Biotechnologies since our coverage began on the company. We intend to sell every share we have purchased in the private placement and on the open market in Stellar Biotechnologies for our own profit. We will sell all of our shares without notice to our subscribers. We may purchase more shares in Stellar Biotechnologies without notice to our subscribers. Please remember, we currently own shares in Stellar Biotechnologies.
Statements included in this newsletter may contain forward looking statements, including any of the mentioned companies' intentions, forecasts, plans or other matters that haven't yet occurred. Such statements involve a number of risks and uncertainties. Further information on potential factors that may affect, delay or prevent such forward looking statements from coming to fruition can be found in their specific Financial reports.
Maximus Strategic Consulting Inc. is a distributor (and not a publisher) of content supplied by third parties and Subscribers. Accordingly, Maximus Strategic Consulting Inc. has no more editorial control over such content than does a public library, bookstore, or newsstand. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by third parties, including information providers, Subscribers or any other user of The Maximus Strategic Consulting Inc. Network of Sites, are those of the respective author(s) or distributor(s) and not of Maximus Strategic Consulting Inc. Neither Maximus Strategic Consulting Inc. nor any third-party provider of information guarantees the accuracy, completeness, or usefulness of any content, nor its merchantability or fitness for any particular purpose.